Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 510(k) clearance granted to pattern scanning laser indirect ophthalmoscope ➤ 12-week safety, efficacy results for wet AMD therapy ➤ Phase 3 trial for dry eye treatment complete ➤ Corneal implant company moves toward PMA submission ➤ Update on neuropathic corneal pain trial ➤ ASCRS news and events
➤ Fast Track Designation granted for investigational retinitis pigmentosa therapy ➤ Three-month data for first-in-class dual inflammasome inhibitor for geographic atrophy ➤ Clinical updates for sustained-release drug implant treating glaucoma ➤ Gene therapy program receives Rare Pediatric Disease Designation ➤ Study: lasting effect of multifocal contact lenses for myopia progression ➤ ASCRS news and events
➤ Topline Phase 3 pivotal study for BRIMOCHOL for treatment of presbyopia ➤ Positive Phase 2b/3 results for oral treatment of thyroid eye disease ➤ Clinical plan for first-in-human trial for investigational dry AMD therapy ➤ Update on registrational program therapy targeting various retinal diseases ➤ Collaboration to develop RNAi program targeting geographic atrophy ➤ ASCRS news and events
➤ NDA submitted for epithelium-on crosslinking therapy ➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis ➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy ➤ Phase 1b study evaluating sozinibercept for DME published ➤ Phase 2 study for topical dry AMD therapy begins ➤ FDA clears IND for gene therapy targeting Stargardt disease ➤ ASCRS news and events
➤ Positive topline data in Phase 1/2 allogenic cell therapy trial ➤ Investigational, light-based treatment for infectious keratitis ➤ Topline results from Phase 3 clinical trial for chronic thyroid eye disease ➤ Primary endpoint met in trial investigating extended dosing interval for retinal vein occlusion treatment ➤ Rare Pediatric Disease Designation granted to investigational retina gene therapy ➤ Merger and acquisition news ➤ ASCRS news and events
➤ Topline results for non-steroidal immunomodulator for postop inflammation ➤ Pilot study describes use of prosthetic device for treatment of dry eye ➤ First patient dosed in Phase 3 trial investigating wet AMD treatment ➤ Acquisition and partnership news ➤ ASCRS news and events
➤ Investigational drug-eluting contact lens for glaucoma sees positive results ➤ First clinical-stage RNA-targeting therapy for nAMD ➤ PDUFA data extended for BLA for treatment of macular telangiectasia ➤ Three rare disease designations granted to investigational gene therapy treatments ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ FDA authorizes first device treatment for dry AMD ➤ Fast track designation granted to retinopathy of prematurity prevention therapy ➤ Fluorescent hydrogel for cataract surgery ➤ ASCRS news and events
➤ Positive topline Phase 3 data for presbyopia drop ➤ Topline results for oral therapy targeting geographic atrophy ➤ Positive topline results from Phase 2 sustained-delivery drug for DME ➤ Study assesses new virtual reality simulator for phaco ➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events